Table 3.
Biomarker levels in 30-day survivors and non-survivors with VA-ECMO.
| VA-ECMO | 30-day survivors | 30-day non-survivors | P values |
|---|---|---|---|
| T1 (within 24 h) | |||
| Procalcitonin | 4 (1–17) | 8 (4–15) | 0.442 |
| DAO | 14 (8–33) | 18 (8–76) | 0.419 |
| Cystatin C | 0.7 (0.4–1.0) | 1.0 (0.3–1.3) | 0.338 |
| T2 (25–48 h) | |||
| Procalcitonin | 4 (1–13) | 10 (4–15) | 0.165 |
| DAO | 9 (5–26) | 13 (5–23) | 0.705 |
| Cystatin C | 0.6 (0.5–1.0) | 1.0 (0.4–1.2) | 0.338 |
| T3 (49–72 h) | |||
| Procalcitonin | 3 (1–5) | 8 (3–12) | 0.022 |
| DAO | 5 (4–11) | 6 (4–13) | 0.752 |
| Cystatin C | 0.7 (0.4–1.0) | 0.9 (0.5–1.2) | 0.209 |
| T4 (73–96 h) | |||
| Procalcitonin | 2 (0–7) | 4 (2–8) | 0.202 |
| DAO | 6 (4–9) | 6 (3–12) | 0.667 |
| Cystatin C | 0.6 (0.4–1.1) | 1.0 (0.6–1.1) | 0.131 |
Data are presented as medians (interquartile ranges), numbers, and percentages as appropriate. Study time points (T1–T4) represent the time after ECMO initiation. DAO, diamine oxidase; VA-ECMO, venoarterial ECMO.